HELIOS Kliniken Schwerin GmbH
- Address
- lock Available on a paid plan
Digestive System Diseases
The Frauenklinik at HELIOS Kliniken Schwerin is conducting studies on colon cancer and advanced gastric adenocarcinoma, aiming to assess new targeted agents and pre‑operative systemic therapies to improve surgical outcomes and survival.
- Colon cancer staging and treatment response
- FGFR2b‑positive stomach and gastro‑esophageal junction adenocarcinoma
- Pre‑operative chemotherapy versus surgery‑first approaches
- Evaluation of novel targeted inhibitors in metastatic disease
Across the site, 24 clinical trials involve 16 investigators, reflecting a strong focus on gastrointestinal oncology.
Eye Diseases
Research at the clinic includes trials for thyroid eye disease, testing biologic agents that aim to reduce proptosis and improve visual function in affected patients.
- Batoclimab therapy for active thyroid eye disease
- Assessment of proptosis responder rates
- Safety monitoring of subcutaneous immunomodulators
- Patient‑reported outcome measures for eye comfort
The eye‑disease program contributes to the overall portfolio of 24 trials at the Schwerin site.
Hemic and Lymphatic Diseases
The department is active in trials addressing acute lymphoblastic leukemia and lymphoblastic lymphoma, evaluating intensive chemotherapy backbones, proteasome inhibition, and novel immunotherapies to boost disease‑free survival.
- High‑risk pediatric Ph+ ALL with imatinib combinations
- Bortezomib addition during consolidation in relapsed ALL
- Blinatumomab post‑consolidation immunotherapy
- Comparative studies of carboplatin versus cisplatin in germ‑cell tumours
These hematologic studies are part of the site’s broader clinical research effort.
Immune System Diseases
Trials focusing on immune checkpoint inhibition explore combinations with chemotherapy in melanoma and triple‑negative breast cancer, seeking to improve progression‑free survival and response rates.
- Atezolizumab plus chemotherapy in triple‑negative breast cancer
- Fianlimab and cemiplimab versus pembrolizumab in advanced melanoma
- Evaluation of PD‑1/PD‑L1 blockade in high‑risk skin cancers
- Biomarker‑driven patient selection for immunotherapy
Immuno‑oncology research complements the site’s extensive oncology portfolio.
Male Urogenital Diseases
The clinic conducts studies on metastatic castration‑resistant prostate cancer and other urologic malignancies, comparing new hormonal agents and combination regimens to enhance overall survival.
- MK‑5684 versus standard androgen‑axis therapies
- Belzutifan plus zanzalintinib compared with cabozantinib in renal cell carcinoma
- Saruparib added to radiotherapy and ADT in high‑risk prostate cancer with BRCA mutation
- Evaluation of novel anti‑androgen combinations
These urogenital cancer trials are integrated within the site’s 24‑trial program.
Neoplasms
A broad spectrum of solid‑tumor investigations, including breast cancer, melanoma, renal cell carcinoma, and gastrointestinal cancers, aims to refine treatment sequencing and assess emerging targeted therapies.
- Early‑stage PIK3CA‑mutated breast cancer with inavolisib
- Advanced melanoma with BRAF V600 mutation treated with encorafenib + binimetinib
- FGFR2b‑positive gastric cancer and bemarituzumab combinations
- Renal cell carcinoma trials with belzutifan combinations
The diverse neoplasm portfolio reflects the site’s commitment to multidisciplinary cancer research.
Nervous System Diseases
Clinical programs target pediatric and adult brain tumors such as medulloblastoma, ependymoma, and glioma, testing intensified radiotherapy schedules and targeted agents to raise event‑free survival.
- Hyperfractionated‑accelerated radiotherapy for high‑risk medulloblastoma
- Post‑operative chemotherapy strategies for ependymoma
- Valproate addition to chemotherapy in radiation‑ineligible children
- Molecularly guided maintenance therapy for medulloblastoma subtypes
These neuro‑oncology trials contribute to the overall research activity at HELIOS Kliniken Schwerin.
Skin and Connective Tissue Diseases
Studies in this area address melanoma and chronic wound healing, evaluating immunotherapy combinations and topical agents to improve disease control and tissue repair.
- Encorafenib + binimetinib for BRAFV600‑mutated melanoma
- Batoclimab for active thyroid eye disease with skin involvement
- Topical allo‑APZ2‑CVU for chronic venous ulcer closure
The skin‑focused research aligns with the site’s comprehensive clinical trial network.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 15 therapeutic areas and 15 of 124 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 120 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1Immunovant Sciences GmbH2active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Immunovant Sciences GmbH3trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HELIOS Kliniken Schwerin GmbH
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 124 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 8 | Unknown | 2015-06-02 | 2024-09-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.